NCT04049617 - Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

March 30, 2021

Study Completion Date

March 30, 2021

Conditions

Advanced Solid Tumors

Interventions

DRUG

Evixapodlin

Tablets administered orally.

Trial Locations (6)

Auckland Clinical Studies Ltd, Grafton, Auckland

Auckland City Hospital, Auckland

Christchurch Clinical Studies Trust, LLC, Christchurch

NEXT Oncology, San Antonio

California Care Associates for Research and Excellence Inc, Encinitas

Northwest Medical Specialties, PLLC, Tacoma